Schematic representation of how monoclonal antibodies are generally made from hybridomas. To make ZMapp, the genes encoding for the antibodies were extracted from the hybridomas, genetically engineered to replace mouse components with human components, and transfected into tobacco plants.[1]
This article is about the drug. It is not to be confused with ZMap.
ZMapp is an experimental biopharmaceutical drug comprising three chimeric monoclonal antibodies under development as a treatment for Ebola virus disease.[1] Two of the three components were originally developed at the Public Health Agency of Canada's National Microbiology Laboratory (NML), and the third at the U.S. Army Medical Research Institute of Infectious Diseases; the cocktail was optimized by Gary Kobinger, a research scientist at the NML[2] and underwent further development under license by Mapp Biopharmaceutical. ZMapp was first used on humans during the Western African Ebola virus epidemic, having only been previously tested on animals and not yet subjected to a randomized controlled trial.[3] The National Institutes of Health (NIH) ran a clinical trial starting in January 2015 with subjects from Sierra Leone, Guinea, and Liberia aiming to enroll 200 people, but the epidemic waned and the trial closed early, leaving it too statistically underpowered to give a meaningful result about whether ZMapp worked.[4]
In 2016, a clinical study comparing ZMapp to the current standard of care for Ebola was inconclusive.[5]
^ abCite error: The named reference Kroll was invoked but never defined (see the help page).
^Branswell, Helen (September 21, 2014). "How a Winnipeg lab became an Ebola research powerhouse". CBC News. The Canadian Press. Retrieved 23 November 2015.
^Cite error: The named reference NYTwho was invoked but never defined (see the help page).
^"Press release: Study Finds Ebola Treatment ZMapp Holds Promise, Although Results Not Definitive | NIH: National Institute of Allergy and Infectious Diseases". National Institute of Allergy and Infectious Diseases. October 12, 2016.
^PREVAIL II (October 13, 2016). "A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection". NEJM. 375 (15): 1448–1456. doi:10.1056/NEJMoa1604330. PMC 5086427. PMID 27732819.
ZMapp is an experimental biopharmaceutical drug comprising three chimeric monoclonal antibodies under development as a treatment for Ebola virus disease...
Diego, California. It is responsible for the research and development of ZMapp, a drug which is still[when?] under development and comprises three humanized...
and other scientists called for the emergency release of the experimental ZMapp vaccine for use on humans before it had undergone clinical testing on humans...
researchers at Mapp Biopharmaceutical used to create the Ebola therapeutic ZMapp. The treatment is credited with saving the lives of two aid workers. For...
2015 Ebola epidemic with the use, by prescription and authorization, of ZMapp and other experimental treatments, and for new drugs that can be used to...
doses of ZMapp,[citation needed] a drug for Ebola virus disease treatment originally developed by Mapp Biopharmaceutical. Supplies of ZMapp ran out in...
discovery and pathology of the Ebola virus; and the development and use of ZMapp, an experimental drug for the Ebola virus which was first administered to...
Midwest Reliability Organization Mapp Biopharmaceutical, manufacturers of ZMapp Ebola vaccine Mapp and Lucia, a series of novels featuring Miss Mapp MAPP...
drug ZMapp. They both recovered, but there was no confirmation or proof that the drug was a factor. A Spanish priest with Ebola had taken ZMapp but died...
are circulating. Example of drugs that use monoclonal antibodies include ZMapp against Ebola and Palivizumab against RSV. Many mABs against other infections...
monoclonal antibodies and other recombinant proteins; for example, the drug ZMapp was produced using these plants. In 2022, a genetically engineered N. benthamiana...
Infectious Diseases (USAMRIID) to fund research on the drug now called ZMapp, which has since been used on several patients. DTRA also funded and managed...
who received ZMapp, the difference was not statistically significant and ultimately it could not be determined whether the use of ZMapp was superior to...
ansuvimab and REGN-EB3 were superior to the comparator ZMapp. Overall mortality of patients in the ZMapp and remdesivir groups were 49% and 53% compared to...
Global Information